Merck & Company Inc (MRK)vsSyndax Pharmaceuticals Inc (SNDX)
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
SNDX
Syndax Pharmaceuticals Inc
$9.54
-0.52%
HEALTHCARE · Cap: $863.37M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23160% more annual revenue ($67.38B vs $289.68M). MRK leads profitability with a 3.6% profit margin vs -72.3%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
SNDX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Intrinsic value data unavailable for SNDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Revenue surging 81.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -189.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SNDX
The strongest argument for SNDX centers on Revenue Growth, Debt/Equity. Revenue growth of 81.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : SNDX
The primary concerns for SNDX are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while SNDX is a hypergrowth play — different risk/reward profiles.
SNDX carries more volatility with a beta of 0.45 — expect wider price swings.
SNDX is growing revenue faster at 81.6% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Syndax Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?